NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a research program targeting pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is funded by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to overcome a key challenge in treating malignant brain tumors: maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, rapid drug clearance from the treatment site often limits therapeutic benefit. The Mayo team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, potentially prolonging therapeutic exposure after localized delivery. The project begins with large animal studies and may expand to human trials if successful.
The study will utilize NeuroOne's investigational drug delivery neural device, which integrates precision intracranial drug delivery with simultaneous neural recording. This approach enables targeted therapy while providing real-time physiologic monitoring, offering insights into drug delivery and its effects on the surrounding neural environment. The CCRF award marks a milestone in advancing this therapeutic approach toward clinical evaluation.
David Wambeke, Chief Business Officer of NeuroOne, stated, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording." He added, "We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors."
NeuroOne's drug delivery platform has attracted growing interest from leading academic investigators and biopharmaceutical companies. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures while improving patient outcomes. NeuroOne is also engaged in research for basivertebral nerve ablation and spinal cord stimulation programs.
For more information, visit nmtc1.com.
